Literature DB >> 18072818

Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids.

Parris M Kidd1.   

Abstract

The omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are orthomolecular, conditionally essential nutrients that enhance quality of life and lower the risk of premature death. They function exclusively via cell membranes, in which they are anchored by phospholipid molecules. DHA is proven essential to pre- and postnatal brain development, whereas EPA seems more influential on behavior and mood. Both DHA and EPA generate neuroprotective metabolites. In double-blind, randomized, controlled trials, DHA and EPA combinations have been shown to benefit attention deficit/hyperactivity disorder (AD/HD), autism, dyspraxia, dyslexia, and aggression. For the affective disorders, meta-analyses confirm benefits in major depressive disorder (MDD) and bipolar disorder, with promising results in schizophrenia and initial benefit for borderline personality disorder. Accelerated cognitive decline and mild cognitive impairment (MCI) correlate with lowered tissue levels of DHA/EPA, and supplementation has improved cognitive function. Huntington disease has responded to EPA. Omega-3 phospholipid supplements that combine DHA/EPA and phospholipids into the same molecule have shown marked promise in early clinical trials. Phosphatidylserine with DHA/EPA attached (Omega-3 PS) has been shown to alleviate AD/HD symptoms. Krill omega-3 phospholipids, containing mostly phosphatidylcholine (PC) with DHA/EPA attached, markedly outperformed conventional fish oil DHA/EPA triglycerides in double-blind trials for premenstrual syndrome/dysmenorrhea and for normalizing blood lipid profiles. Krill omega-3 phospholipids demonstrated anti-inflammatory activity, lowering C-reactive protein (CRP) levels in a double-blind trial. Utilizing DHA and EPA together with phospholipids and membrane antioxidants to achieve a triple cell membrane synergy may further diversify their currently wide range of clinical applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18072818

Source DB:  PubMed          Journal:  Altern Med Rev        ISSN: 1089-5159


  79 in total

Review 1.  Omega-3 Supplementation as a Dietary Intervention to Reduce Aggressive and Antisocial Behavior.

Authors:  Olivia Choy; Adrian Raine
Journal:  Curr Psychiatry Rep       Date:  2018-04-05       Impact factor: 5.285

Review 2.  Is prevention a realistic goal for schizophrenia?

Authors:  Christian Kohler; Karin E Borgmann-Winter; Irene Hurford; Eli Neustadter; James Yi; Monica E Calkins
Journal:  Curr Psychiatry Rep       Date:  2014-04       Impact factor: 5.285

Review 3.  Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research.

Authors:  Akiko Hayashi-Takagi; Marquis P Vawter; Kazuya Iwamoto
Journal:  Biol Psychiatry       Date:  2013-10-18       Impact factor: 13.382

4.  Omega-3 fatty acids moderate effects of physical activity on cognitive function.

Authors:  Regina L Leckie; Stephen B Manuck; Neha Bhattacharjee; Matthew F Muldoon; Janine M Flory; Kirk I Erickson
Journal:  Neuropsychologia       Date:  2014-05-09       Impact factor: 3.139

5.  Deficit in prepulse inhibition in mice caused by dietary n-3 fatty acid deficiency.

Authors:  Irina Fedorova; Anita R Alvheim; Nahed Hussein; Norman Salem
Journal:  Behav Neurosci       Date:  2009-12       Impact factor: 1.912

6.  Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.

Authors:  P A Dacks; D W Shineman; H M Fillit
Journal:  J Nutr Health Aging       Date:  2013-03       Impact factor: 4.075

7.  Production of Lipids and Proteome Variation in a Chilean Thraustochytrium striatum Strain Cultured under Different Growth Conditions.

Authors:  Carolina Shene; Marcelo Garcés; Daniela Vergara; Jhonatan Peña; Stéphane Claverol; Mónica Rubilar; Allison Leyton
Journal:  Mar Biotechnol (NY)       Date:  2018-11-19       Impact factor: 3.619

8.  Anthroposophic therapy for attention deficit hyperactivity: a two-year prospective study in outpatients.

Authors:  Harald J Hamre; Claudia M Witt; Gunver S Kienle; Christoph Meinecke; Anja Glockmann; Renatus Ziegler; Stefan N Willich; Helmut Kiene
Journal:  Int J Gen Med       Date:  2010-08-30

9.  Screening of marine bacterial producers of polyunsaturated fatty acids and optimisation of production.

Authors:  Ahmed Abd El Razak; Alan C Ward; Jarka Glassey
Journal:  Microb Ecol       Date:  2013-11-30       Impact factor: 4.552

10.  Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder.

Authors:  Pieter Stolk; Patrick C Souverein; Ingeborg Wilting; Hubert G M Leufkens; Donald F Klein; Stanley I Rapoport; Eibert R Heerdink
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-11-25       Impact factor: 4.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.